Autres langues Knight Therapeutics Inc.

Actions

GUD

CA4990531069

Temps Différé Toronto S.E. Autres places de cotation 17:20:57 29/04/2024			Varia. 5j.	Varia. 1 janv.
5,77 ^CAD	+0,70%		-0,35%	+11,18%

22/03	KNIGHT THERAPEUTICS INC. : RBC Capital Markets favorable sur le dossier	ZM
21/03	Knight Therapeutics annonce ses résultats du quatrième trimestre	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity	28/03
Knight Therapeutics Reports Fourth Quarter Results	21/03
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024	21/03
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Knight Therapeutics Inc. Announces Impairment Charges for the Fourth Quarter of 2023	21/03
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results	21/03
Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
North American Morning Briefing : Investors -2-	21/03
North American Morning Briefing : Investors Continue to Cheer Reassuring Fed	21/03
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call	14/03
Knight Therapeutics Announces Launch of Minjuvi in Brazil	29/02
Knight Therapeutics Brief: Announcing Launch of Minjuvi in Brazil	29/02
Knight Therapeutics Announces Launch of Minjuvi® in Brazil	29/02
Knight Therapeutics Announces Launch of Minjuvi® in Brazil	29/02
Knight Therapeutics Inc. Celebrates its First Decade of Success	28/02
Knight Therapeutics Brief: Announcing Regulatory Submission Of Fostamatinib In Brazil	21/02
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil	21/02
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil	21/02
Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil	21/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Knight Therapeutics Inc.

Actions

GUD

CA4990531069

Autres langues

Filtres